Last edition
News about Biotechnology
Zydus to Commercialise Keytruda Biosimilar FYB206 in US and Canada
Zydus Lifesciences has entered into an exclusive licensing agreement with Germany-based Formycon AG to commercialise FYB206, a biosimilar of the immunotherapy drug Keytruda (pembrolizumab), in the United States and Canada.
Biotechnology | 10/12/2025 | By Darshana | 210
Dr. Reddy's Signs USD 370 Million Licensing Deal for Eftilagimod Alfa
Dr. Reddy’s Laboratories has entered into an exclusive licensing agreement with Australian biotechnology company Immutep to commercialise its investigational immunotherapy, Eftilagimod Alfa (Efti), across markets outside North America, Europe, Japan and Greater China.
Biotechnology | 09/12/2025 | By Darshana | 122
Rondo Therapeutics Begins First-in-Human Trial of Novel CD28 - Nectin-4 Bispecific for Solid Tumours
Rondo Therapeutics, a clinical-stage biopharmaceutical company developing next-generation T-cell engaging bispecific antibodies for solid tumours, has begun dosing patients in its phase 1/1b clinical trial of RNDO-564.
Biotechnology | 07/12/2025 | By Darshana | 278
Cytiva and Veeda Lifesciences Launch New HCP Services Centre
The collaboration between Cytiva and Veeda Lifesciences brings a dedicated Host Cell Protein (HCP) services centre offering comprehensive HCP coverage, characterization, and quantification assays, enabling global biopharma companies to enhance the safety, efficacy, and quality of their biologics development
Biotechnology | 28/11/2025 | By Dineshwori | 217
Teva secures EC approval for two denosumab biosimilars, Ponlimsi and Degevma
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has received marketing authorizations from the European Commission for its two denosumab biosimilars—Ponlimsi, referencing Prolia, and Degevma, referencing Xgeva.
Biotechnology | 27/11/2025 | By Darshana | 191
Biogen Inc. has entered into a research collaboration with Dayra Therapeutics to discover and develop oral macrocyclic peptides targeting high-priority immunological conditions.
Biotechnology | 26/11/2025 | By Darshana | 156
Harbour BioMed Advances Global Biotherapeutics Collaboration With AstraZeneca
The alliance focuses on discovering and developing next-generation biotherapeutics, including antibody-drug conjugates and T-cell engagers, by combining the scientific strengths of both companies.
Biotechnology | 25/11/2025 | By Darshana | 171
Freudenberg Expands Bioprocessing Capabilities at CPHI and PMEC India
The global manufacturer has introduced its CleanAssure system, a cleanroom-based sanitary washing and drying workstation that uses ultra-purified water and filtered air to enhance safety for single-use tubings and assemblies.
Biotechnology | 25/11/2025 | By Darshana | 160
India Unveils its First Indigenous CRISPR-based Gene Therapy 'BIRSA 101' for Sickle Cell Disease
India has formally begun its decisive journey towards becoming a Sickle Cell Disease–free nation, with Union Minister of State for Science & Technology Dr. Jitendra Singh launching the country's first indigenous CRISPR-based gene therapy for the condition.
Biotechnology | 20/11/2025 | By Dineshwori | 734
EirGenix Signs Second Global Licensing Deal With Sandoz for Pertuzumab Biosimilar
EirGenix Inc., a Taiwan-based biopharmaceutical and CDMO company, has signed a second global exclusive licensing agreement with Sandoz AG for the commercialization of its pertuzumab biosimilar EG1206A, developed as an alternative to Roche’s Perjeta.
Biotechnology | 14/11/2025 | By Darshana | 261
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy